Laurus Labs Reports Q1 2025 Financial Results with 34.89% Stake in ImmunoAdoptive Cell Therapy

Laurus Labs Ltd. has released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The company reported a revenue from operations of 1,569.57 crores, with a net profit after tax of 40.00 crores. The Board of Directors approved these results in a meeting on July 25, 2025. The company has also invested 40 crores in Laurus Bio Private Limited and holds a 49.00% stake in KRKA Pharma Private Limited as a joint venture. Laurus Labs has accounted for its investment in Kurnool Renewables Private Limited as an associate. The company has recorded a profit for the period attributable to equity holders of the company of 4.33 crores (not annualised).